An evaluation of hydromethylthionine as a treatment option for Alzheimer’s disease (2020)

Peer-Reviewed Study · Hashweh NN, Bartochowski Z, Khoury R, Grossberg GT · February 8, 2020

Hashweh NN et al., 2020-02-08: Independent-style review of hydromethylthionine for Alzheimer's disease which states plainly that the randomized trials failed, and that the positive signal comes from a non-randomized cohort in which the low 'placebo' dose was given as monotherapy.

Randomized clinical trials with hydromethylthionine failed to show any impact of the doses used on the disease course.

abstract

Hashweh NN et al., 2020-02-08: Independent-style review of hydromethylthionine for Alzheimer's disease which states plainly that the randomized trials failed, and that the positive signal comes from a non-randomized cohort in which the low 'placebo' dose was given as monotherapy. Study type: narrative review (secondary source). N/A. Countries: trials reviewed are multinational. Doses reviewed: 8 mg/day 'placebo' through 250 mg/day hydromethylthionine. Funders/conflicts: see the paper's declaration section (not in abstract). Important because it states the methodological objection in neutral language: the monotherapy finding is from a non-randomized subgroup, later modelled pharmacokinetically (MTK-20), not from a randomized comparison. Study type: review.